Imprese · 17/07/20201 min di lettura
Eli Lilly and Co.; Announcement of the Revocation of the Biologics License for LARTRUVO
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license application (BLA) for LARTRUVO (olaratumab) injection. Eli Lilly and Co. requested withdrawal (revocation) of the biologics license application and has waived its opportunity for a hearing.